Anti-PD-1 or anti-CTLA-4 in first line therapy?

Anti-PD-1 or anti-CTLA-4 in first line therapy?

33 First Line Therapy for HER2- PDL1+ GEAПодробнее

33 First Line Therapy for HER2- PDL1+ GEA

Kidney Cancer Conference Highlights from ASCO 2022Подробнее

Kidney Cancer Conference Highlights from ASCO 2022

The current treatment landscape and future directions of combination approaches for HCCПодробнее

The current treatment landscape and future directions of combination approaches for HCC

Beyond anti-PD-1 and anti-CTLA-4 in melanomaПодробнее

Beyond anti-PD-1 and anti-CTLA-4 in melanoma

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

Immune Checkpoint Inhibition in Myeloid MalignanciesПодробнее

Immune Checkpoint Inhibition in Myeloid Malignancies

MelanomaПодробнее

Melanoma

On the Horizon: Emerging Therapies to WatchПодробнее

On the Horizon: Emerging Therapies to Watch

Immunotherapy Combinations as First-Line TherapyПодробнее

Immunotherapy Combinations as First-Line Therapy

Immune checkpoint inhibitors and combination strategies for patients with gastric cancerПодробнее

Immune checkpoint inhibitors and combination strategies for patients with gastric cancer

Immunotherapy in Renal Cell CarcinomaПодробнее

Immunotherapy in Renal Cell Carcinoma

Dr. McDermott on the Use of Anti–PD-1 Combinations in mRCCПодробнее

Dr. McDermott on the Use of Anti–PD-1 Combinations in mRCC

Targeting the immune system with checkpoint inhibitorsПодробнее

Targeting the immune system with checkpoint inhibitors

Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhDПодробнее

Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD

James P. Allison, Ph.D., on Targeting Immune Checkpoints in Cancer TherapyПодробнее

James P. Allison, Ph.D., on Targeting Immune Checkpoints in Cancer Therapy

Immune Checkpoint InhibitorsПодробнее

Immune Checkpoint Inhibitors

Immunoregulation and T cell Tolerance with Arlene Sharpe, MD, PhDПодробнее

Immunoregulation and T cell Tolerance with Arlene Sharpe, MD, PhD

Immunotherapy/Checkpoint Inhibitor, Targeted Immunotherapy Drugs 5/2/18Подробнее

Immunotherapy/Checkpoint Inhibitor, Targeted Immunotherapy Drugs 5/2/18